Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA:600420)

China flag China · Delayed Price · Currency is CNY
8.70
-0.20 (-2.25%)
Jun 9, 2026, 3:00 PM CST
Market Cap11.67B -15.8%
Revenue (ttm)8.82B -15.4%
Net Income718.59M -35.5%
EPS0.54 -35.5%
Shares Out 1.34B
PE Ratio16.24
Forward PEn/a
Dividend0.30 (3.37%)
Ex-Dividend DateJun 3, 2026
Volume6,561,379
Open8.83
Previous Close8.90
Day's Range8.66 - 8.88
52-Week Range8.68 - 11.80
Beta0.12
Analystsn/a
Price Targetn/a
Earnings DateAug 28, 2026

About SHA:600420

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and cefoperazone dispersible tablets; and cefuroxime axetil tablets, cefuroxime sodium for injection, cefaclor extended-release capsules, cefixime granule... [Read more]

Sector Healthcare
Founded 1996
Employees 9,697
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600420
Full Company Profile

Financial Performance

In 2025, SHA:600420's revenue was 9.36 billion, a decrease of -14.39% compared to the previous year's 10.94 billion. Earnings were 941.60 million, a decrease of -13.11%.

Financial Statements